WINT - windtreetx.com Long-Term Liabilities to Capital

The prospects for Windtree Therapeutics (WINT) rely on the efficacy and safety of istaroxime in the treatment of heart failure. This daily price action on GURU.Markets reflects debt obligations, which stand at 0.00. While management focuses on bringing innovative drugs to critically ill patients, a lack of funds and frequent secondary offerings create significant risks of shareholder dilution.

This indicator is sensitive to fluctuations in operating expenses that impact the size of equity. The metric measures the share of long-term liabilities within the financing structure, determining the business's degree of dependence on borrowed funds. For Windtree Therapeutics (WINT), this is critical when financing costly R&D developments in cardiovascular bioengineering. High scientific potential requires stable capital. Analysis of this long-term debt-to-equity chart allows for an assessment of the sustainability of the debt load.